(2-氟-4,5-二甲氧基苯基)甲醇 | 79474-33-2

• 分子结构分类: 有机化合物 - 苯类化合物 - 苯和取代衍生物
• 中文名称: (2-氟-4,5-二甲氧基苯基)甲醇
• 英文名称: 2-fluoro-4,5-dimethoxybenzyl alcohol
• 英文别名: (2-fluoro-4,5-dimethoxy-phenyl)-methanol；(2-Fluoro-4,5-dimethoxyphenyl)methanol
• CAS: 79474-33-2
• 化学式: C₉H₁₁FO₃
• 分子量: 186.183
• InChiKey: XXVHZRSCHQVCTB-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  1.1
• 重原子数：
  13
• 可旋转键数：
  3
• 环数：
  1.0
• sp3杂化的碳原子比例：
  0.33
• 拓扑面积：
  38.7
• 氢给体数：
  1
• 氢受体数：
  4

反应信息

• 作为反应物：
  描述：

  (2-氟-4,5-二甲氧基苯基)甲醇 在 三溴化磷 、 sodium hydroxide 作用下， 以 乙醇 、 二氯甲烷 、 乙腈 为溶剂， 反应 4.08h， 生成 7-[3-(benzylideneamino)methyl-4-(3',4'-dimethxoy-6'-fluorobenzyloxyimino)pyrrolidin-1-yl]-1-cyclopropyl-6-fluoro-1,4-dihydro-4-oxo-1,8-naphthyridine-3-carboxylic acid
  参考文献：
  名称：

  Synthesis and in vitro antibacterial activity of gemifloxacin derivatives containing a substituted benzyloxime moiety

  摘要：

  A series of novel gemifloxacin (GMFX) derivatives containing a substituted benzyloxime moiety with remarkable improvement in lipophilicity were synthesized. The target compounds evaluated for their in vitro antibacterial activity against representative strains. Our results reveal that most of the target compounds have considerable potency against all of the tested Gram-positive strains including MRSA and MRSE (MIC: <0.008-8 mu g/mL), although they are generally less active than the references against the Gram-negative strains. In particular, compound 111 (MIC: <0.008-4 mu g/mL) was found to be 8-2048 and 2-128 times more potent than levofloxacin (LVFX) and GMFX against the Gram-positive strains, respectively. Moreover, against MRSA clinical isolates, 111 (MIC90: 1 mu g/mL) is 8-fold more active than GMFX, and 2-fold more active than GMFX and moxifloxacin against MRSE clinical isolates (MIC90: 4 mu g/mL). Crown Copyright (C) 2012 Published by Elsevier Masson SAS. All rights reserved.

  DOI：

  10.1016/j.ejmech.2012.07.010
• 作为产物：
  描述：

  6-氟藜芦醛 在 sodium tetrahydroborate 作用下， 以 乙醇 、 水 为溶剂， 反应 0.25h， 以95%的产率得到(2-氟-4,5-二甲氧基苯基)甲醇
  参考文献：
  名称：

  通过手性相转移烷基化高对映选择性合成无载流子添加的 6-[18F] 氟-L-多巴

  摘要：

  [18F] 氟-L-多巴是一种重要的正电子发射断层扫描 (PET) 放射性药物，已使用相转移烷基化反应合成。源自金鸡纳生物碱的手性季铵盐用作甘氨酸衍生物的对映选择性烷基化的相转移催化剂。这种席夫碱底物的活性亚甲基被氢氧化铯去质子化，并被 2-[18F] 氟-4,5-二甲氧基苄基卤化物（X = Br，I）迅速烷基化。该反应在 0°C 或室温下在甲苯或二氯甲烷等各种溶剂中以高产率 (> 90%) 进行。开发了在固体载体上制备 [18F] 烷基化剂。贴上标签后，标记的 [18F] 氟藜芦醛被捕获在 tC18 小柱上，然后通过加入硼氢化钠水溶液和气态氢溴酸或碘酸在小柱上转化为相应的苄基卤衍生物。通过制备型 HPLC 进行水解和纯化，使 6-[18F] 氟-L-多巴在 100 分钟的合成时间内以 25-30% 衰减校正的放射化学产率准备用于人体注射。发现该产品是化学、放射化学和对映异构体纯的（ee >

  DOI：

  10.1002/ejoc.200400059

文献信息

• 2-Aminopurine analogs having HSP90-inhibiting activity
  申请人：Kasibhatla Rao Srinivas

  公开号：US20050113340A1

  公开（公告）日：2005-05-26

  2-Aminopurine analogs are described and demonstrated or predicted to have utility as Heat Shock Protein 90 (HSP90) inhibiting agents in the treatment and prevention of various HSP90 mediated disorders, e.g., proliferative disorders. Method of synthesis and use of such compounds are also described and claimed.

  本文描述了2-氨基嘌呤类似物，并展示或预测其作为热休克蛋白90（HSP90）抑制剂，在治疗和预防各种HSP90介导的疾病，例如增殖性疾病方面具有实用性。还描述和声明了这些化合物的合成方法和使用方法。
• 2-aminopurine analogs having HSP90-inhibiting activity
  申请人：Conforma Therapeutics Corporation

  公开号：US07138401B2

  公开（公告）日：2006-11-21

  2-Aminopurine analogs are described and demonstrated or predicted to have utility as Heat Shock Protein 90 (HSP90) inhibiting agents in the treatment and prevention of various HSP90 mediated disorders, e.g., proliferative disorders. Method of synthesis and use of such compounds are also described and claimed.

  描述了2-氨基嘌呤类似物，并证明或预测其在治疗和预防各种HSP90介导的疾病，例如增殖性疾病中作为热休克蛋白90（HSP90）抑制剂的效用。还描述和声明了这些化合物的合成方法和用途。
• 2-Aminopurine Analogs Having HSP90-Inhibiting Activity
  申请人：Kasibhatla Rao Srinivas

  公开号：US20070185064A1

  公开（公告）日：2007-08-09

  2-Aminopurine analogs are described and demonstrated or predicted to have utility as Heat Shock Protein 90 (HSP90) inhibiting agents in the treatment and prevention of various HSP90 mediated disorders, e.g., proliferative disorders. Method of synthesis and use of such compounds are also described and claimed.

  本文描述了2-氨基嘌呤类似物，并证明或预测其在治疗和预防各种HSP90介导的疾病（如增生性疾病）中作为HSP90抑制剂具有实用价值。还描述和声称了这种化合物的合成方法和使用方法。
• 6-Fluorodihydroxyphenylalanines, a process for preparing and a pharmaceutical composition containing the same
  申请人：Merck & Co., Inc.

  公开号：EP0027993A1

  公开（公告）日：1981-05-06

  Novel 6-Fluorohydroxyphenylalanines, their preparation and pharmaceutical compositions containing the same are disclosed. The novel 6-Fluorohydroxyphenylalanines have the formula and pharmaceutically acceptable salts thereof wherein R is H or CH3 and R1 is H, C1-C18 alkyl or substituted C1-C3 alkyl.

  本发明公开了新型 6-氟羟基苯丙氨酸、其制备方法以及含有这些物质的药物组合物。 新型 6-氟羟基苯丙氨酸具有如下式及其药学上可接受的盐 其中 R 是 H 或 CH3，R1 是 H、C1-C18 烷基或取代的 C1-C3 烷基。
• Deazapurine derivatives as HSP90-Inhibitors
  申请人：Conforma Therapeutics Corporation

  公开号：EP2145888A1

  公开（公告）日：2010-01-20

  Heterobicyclic compounds of formula I are described and demonstrated to have utility as Heat Shock Protein 90 (HSP90) inhibiting agent. Method of synthesis and use of such compounds are also described.

  描述并证明了式 I 的杂双环化合物作为热休克蛋白 90（HSP90）抑制剂的实用性。还描述了合成和使用此类化合物的方法。